All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
• If it can raise enough capital in the near term, Omni Bio Pharmaceutical Inc., of Denver, said it plans to begin two new clinical trials to test the efficacy of alpha-1 antitrypsin as a treatment for Type I diabetes and graft-vs.-host disease (GVHD).